Download Free Sex Drugs And Hiv Aids In Brazil Book in PDF and EPUB Free Download. You can read online Sex Drugs And Hiv Aids In Brazil and write the review.

At the beginning of the twenty-first century, Brazil ranked second only to the United States in the number of reported cases of AIDS. Because Brazil's extensive poverty and inequality, its fragile economic situation, and its limited network of health services, the scarce prevention/intervention resources targeted only the most visible at risk populations -- gay men, sailors, prostitutes, and street children. Virtually forgotten were Brazil's hidden drug users, as well as the tens of millions of individuals living in the country's thousands of favelas, or shantytowns, which are a characteristic part of almost every Brazilian city. In Sex, Drugs, and HIV/AIDS in Brazil the authors examine the emergence of AIDS in Brazil, its linkages to drug use and the sexual culture, and its epidemiology in such populations as cocaine users, "street children," and male transvestite prostitutes. Special attention is focused on an HIV/AIDS community outreach program established in Rio de Janeiro, which represented the first such prevention/intervention program in all of Brazil targeting indigent cocaine users. This 6-year initiative was funded by the U.S. National Institute on Drug Abuse, and carried out by the authors of this book. The research combines anthropological, sociological, and biological perspectives; all data were gathered through empirical and ethnographic techniques.
First published in 1993. Routledge is an imprint of Taylor & Francis, an informa company.
The first book on the shocking reality of AIDS in Latin America.
This study assesses the potential demand by the public sector for a preventive HIV/AIDS vaccine in Brazil and the costs of alternative strategies for a vaccination program. Brazil has a mature AIDS epidemic: the percent of the population living with HIV or AIDS (about 0.6 percent of adults) is not as high as in other severely affected developing countries, but infection rates in specific risk groups in the population are very high and HIV has spread beyond these groups into the general population of low-risk individuals. Preventive HIV/AIDS vaccines are still in the testing stage. The characteristics of the first vaccines developed, in terms of their efficacy, duration of effectiveness, ease of administration, and price, are still unknown. But the potential benefits of such a vaccine in Brazil would be high. The study reviews the cost and impact of HIV/AIDS in Brazil, in terms of disease and economic burden, as a proxy for the benefits of an HIV/AIDS vaccine. The epidemiology of AIDS and Brazil's experience with immunization coverage with other vaccines are used to assess the number of vaccines, delivery strategies, and possible costs of an HIV/AIDS immunization program in Brazil, assuming the availability of a 100 percent effective AIDS vaccine that lasts a lifetime under different pricing and dosing assumptions. A low-cost, highly effective vaccine would likely be affordable to an upper-middle-income country like Brazil and yield large benefits from a policy of universal, publicly subsidized immunization. But if prices are higher and the impact less favorable, the costs and effects would have to be compared with other AIDS prevention programs or other health interventions. Both political and economic considerations will likely figure into public policy on HIV/AIDS vaccination, when such a vaccine is developed.
The Census Bureau of the U.S. Department of Commerce presents demographic data on HIV/AIDS in Brazil. The bureau includes epidemiological data, including data on HIV in pregnant women, HIV in blood donors, and HIV in patients with sexually transmitted diseases (STD), HIV in drug users, and HIV in sex workers in Brazil.
Complete with an impressive collection of complex background and research on HIV/AIDS and a foreword by Dr. Peter Piot, former Executive Director of UNAIDS, this volume collects and critically analyzes a wide range of international case studies, detailing why and how businesses take action on HIV/AIDS and providing a wealth of information on the impact of the pandemic.